Courtney Marecki holds up a test tube of clear liquid in a Seattle lab. The centrifuge has just stopped. “Now we have the stuff we don’t want in the bottom and the stuff we do want remained,” the University of Washington chemist says. What is in the tube is a vaccine for fentanyl.
The idea is to prevent overdoses before they happen. A vaccinated person would make antibodies that bind fentanyl in the blood, leaving it too large to cross the barrier that protects the brain. Overdose happens when the drug dulls the brain so much that breathing stops. Block the drug and, researchers hope, you block that.
Teaching the body to see a decoy
Opioids are very small molecules, and the immune system ignores them. “They enter the brain undetected by the body’s immune system because they’re not large enough to elicit an immune response,” Marecki says.
So the lab in Marco Pravetoni’s group builds a copycat of fentanyl, called a hapten, that looks like an opioid in structure but does not act like one. Many of these decoys are attached to a much larger protein the immune system can see. Marecki compares it to “putting a small smiley face sticker on a stop sign.” When real fentanyl shows up later, the antibodies bind to it.
Pravetoni says the antibodies seem to do more than block the drug. “We see that in animal models and even in our preliminary clinical data with the oxycodone vaccine,” he says, pointing to effects on craving. Early data suggests the protection could last up to a year.
Where the trials stand
The Washington lab has already developed vaccines for oxycodone, heroin and fentanyl. The oxycodone vaccine is in human trials. The FDA has cleared the heroin vaccine to begin them. For fentanyl, the team plans to submit an Investigational New Drug application soon. Human testing runs in three phases, and the full approval process can take 10 years.
A separate fentanyl vaccine is further along. It was developed with Department of Defense funding and licensed to the startup ARMR Sciences. According to Fox News, it protected mice and rats, and the animals still had antibodies six months after vaccination. A Phase 1 trial of about 40 participants is slated to begin in early 2026 at the Center for Human Drug Research in the Netherlands, affiliated with the University of Leiden. It will look at safety and immune response. The main limitation, Fox noted, is that so far the data come only from animal models, so how well it works in people is unknown.
One tool, not a cure
Pravetoni does not call his vaccine a cure for addiction. “With addiction there is this perception that we have to come up with a silver bullet medication,” he says. Nobody would blink at a diabetes patient taking three or five medications at once, he adds.
Naomi Lee, a biochemist at Northern Arizona University who is not part of his lab, agrees that a vaccine would work best alongside behavioral health care. “Maybe they needed an extra boost to help them get over that addiction, but you still have to treat the addiction,” she says.
The Washington team is already looking at newer drugs, including xylazine and nitazenes, which can be even more potent than fentanyl. Its longer-term plan is a vaccine that targets several drugs at once.
Sources
- Experimental vaccine could save thousands of lives per year, scientist claims
- Northwest researchers develop vaccines to prevent opioid overdose and support addiction recovery





